Literature DB >> 30648558

Evaluation of the sensitivity to chlorhexidine, voriconazole and itraconazole of T4 genotype Acanthamoeba isolated from Mexico.

Dolores Hernández-Martínez1, María Reyes-Batlle2, Ismael Castelan-Ramírez1, Perla Hernández-Olmos1, Virginia Vanzzini-Zago3, Elizabeth Ramírez-Flores1, Inés Sifaoui2, José E Piñero2, Jacob Lorenzo-Morales2, Maritza Omaña-Molina4.   

Abstract

Free-living amoebae of the genus Acanthamoeba are the etiological agents of cutaneous lesions, granulomatous amoebic encephalitis (GAE) and amoebic keratitis (AK), which are chronic infections with poor prognosis if not diagnosed promptly. Currently, there is no optimal therapeutic scheme to eradicate the pathologies these protozoa cause. In this study we report the morphological and molecular identification of three species of the genus Acanthamoeba, belonging to T4 group; A. polyphaga isolated from the corneal ulcer of a patient sample of AK case; A. castellanii isolated from the contact lens of an AK patient and A. palestinensis obtained from a soil sample. The in vitro activity of chlorhexidine, itraconazole and voriconazole drugs against trophic stage was also evaluated through a colorimetric assay based on the oxidation-reduction of alamar blue. The strains in the study were sensitive to the evaluated drugs; although when determining the 50% inhibitory concentration (IC50) statistically significant differences were observed. A. castellanii showed to be highly sensitive to voriconazole (0.66 ± 0.13 μM) but the least sensitive to chlorhexidine and itraconazole (8.61 ± 1.63 and 20.14 ± 4.93 μM, respectively), A. palestinensis showed the highest sensitivity to itraconazole (0.502 ± 0.11 μM) and A. polyphaga expressed moderate sensitivity to chlorhexidine and itraconazole and lower sensitivity to voriconazole (10.10 ± 2.21 μM). These results showed that species of the genus Acanthamoeba express different sensitivity to the tested drugs, which could explain the problems surrounding the establishment of a treatment of choice in the infections caused by these amoebae. We consider that although chlorhexidine and itraconazole show good activity on these amoebae and have been used in cases of AK in Mexico with acceptable results, voriconazole should be considered as the first therapeutic option of future Acanthamoeba infections that will be diagnosed in our country.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Acanthamoeba, Mexico; Chemotherapy assays; Chlorhexidine; Itraconazole; Voriconazole

Mesh:

Substances:

Year:  2019        PMID: 30648558     DOI: 10.1016/j.exppara.2019.01.006

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  5 in total

1.  Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium.

Authors:  Kirti Megha; Megha Sharma; Chayan Sharma; Amit Gupta; Rakesh Sehgal; Sumeeta Khurana
Journal:  Eye (Lond)       Date:  2021-09-21       Impact factor: 4.456

2.  Application of Histone Deacetylase Inhibitors MPK472 and KSK64 as a Potential Treatment Option for Acanthamoeba Keratitis.

Authors:  Hae-Ahm Lee; So-Min Park; Ki-Back Chu; Fu-Shi Quan; Thomas Kurz; Marc Pflieger; Eun-Kyung Moon
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

3.  Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.

Authors:  Brian Shing; Mina Balen; James H McKerrow; Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-05-19       Impact factor: 5.091

4.  Orthokeratology lens-related Acanthamoeba keratitis: case report and analytical review.

Authors:  Jinfang Wu; Huatao Xie
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

5.  The Antifungal Drug Isavuconazole Is both Amebicidal and Cysticidal against Acanthamoeba castellanii.

Authors:  Brian Shing; Seema Singh; Larissa M Podust; James H McKerrow; Anjan Debnath
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.